Revolution Medicines, Inc.

As of June 30, 2026, Revolution Medicines, Inc. carries a market capitalization of 27.37B, placing it among publicly traded companies globally. Its enterprise value stands at 24.71B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Revolution Medicines, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Revolution Medicines, Inc. has 214.24M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Revolution Medicines, Inc. maintains a current ratio of 11.38, meaning it holds 11.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.63, indicating elevated leverage, while an interest coverage ratio of -27.04 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Revolution Medicines, Inc. posted a negative return on equity (ROE) of -79.09, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -52.37, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 795.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Revolution Medicines, Inc. generated - - in revenue and converted that into -1.43B in net income, yielding earnings per share of -7.19. EBITDA reached -1.30B, while operating income came in at -1.31B.

As of June 30, 2026, Revolution Medicines, Inc. holds 3.18B in cash and equivalents against 518.57M in total debt, resulting in a net debt position of -264.97M. Total book value stands at 2.11B, with working capital of 2.97B providing operational flexibility.

Revolution Medicines, Inc. produced -1.27B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -8.59M in capital expenditures, free cash flow totaled -1.28B - equivalent to -6.45 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.05: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.63, meaning Revolution Medicines, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Revolution Medicines, Inc. has an Altman Z-Score of 10.31, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.